# Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis

> **NCT04863183** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle** · enrollment: 30 (estimated)

## Conditions studied

- Mesenchymal Stem Cells
- Knee Osteoarthritis
- Cell Therapy

## Interventions

- **BIOLOGICAL:** CELLISTEM-OA
- **DRUG:** Triamcinolone acetonide

## Key facts

- **NCT ID:** NCT04863183
- **Lead sponsor:** Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04863183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04863183, "Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04863183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*